Brief: Seagen Says Adcetris Plus Novel Immunotherapy Combination Delivers 100% Progression Free Survival At 12 Months In Phase 2 Trial Of Patients
11/12/2023 24:39
Dec 10 (Reuters) - Seagen Inc SGEN.O :
* ADCETRIS® (BRENTUXIMAB VEDOTIN) PLUS NOVEL IMMUNOTHERAPY
COMBINATION DELIVERS 100% PROGRESSION FREE SURVIVAL AT 12 MONTHS
IN PHASE 2 TRIAL OF PATIENTS WITH EARLY STAGE CLASSICAL HODGKIN
LYMPHOMA
* SEAGEN INC - 88% OF PATIENTS WITH ADVANCED STAGE CLASSICAL
HODGKIN LYMPHOMA IN TRIAL REMAINED PROGRESSION FREE AT 24 MONTHS
* SEAGEN - REGIMEN CONTINUES TO SHOW CONSISTENT SAFETY AND
TOLERABILITY PROFILE, WITH NO CASES OF FEBRILE NEUTROPENIA AND
NO NEW SAFETY SIGNALS OBSERVED
Source text for Eikon: ID:nBwcdbRWza
Further company coverage: SGEN.O
((Reuters.Briefs@thomsonreuters.com;))